Rchr
J-GLOBAL ID:201801013765128857   Update date: May. 21, 2020

Nishio Makoto

Nishio Makoto
Affiliation and department:
Research field  (1): Respiratory medicine
Papers (123):
  • Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney K, Corre R, Franke FA, Richardet E, Penrod JR, Yuan Y, Nathan FE, Bhagavatheeswaran P, DeRosa M, Taylor F, Lawrance R, Brahmer J. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. European journal of cancer (Oxford, England : 1990). 2019. 116. 137-147
  • Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Nishio M. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Lung cancer (Amsterdam, Netherlands). 2019. 133. 4-9
  • Hirashima T, Satouchi M, Hida T, Nishio M, Kato T, Sakai H, Imamura F, Kiura K, Okamoto I, Kasahara K, Uchida H, Vowler SL, Mitsudomi T. Osimertinib for Japanese Patients with T790M-positive Advanced Non-Small Cell Lung Cancer: A Pooled Subgroup Analysis. Cancer science. 2019
  • Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T. Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung C. Lung cancer (Amsterdam, Netherlands). 2019. 132. 157-158
  • Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T. Corrigendum to "Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer" [Lung Cancer 121 (July) (2018) Pages 37-40]. Lung cancer (Amsterdam, Netherlands). 2019. 132. 160
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page